NewAmsterdam Pharma Co NV
NAMS
Company Profile
Business description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Contact
Gooimeer 2-35
NaardenNH1411 DC
NLDT: +31 352062971
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
77
Stocks News & Analysis
stocks
Cheapest ASX member of our Best Idea’s list
This share is trading at the lowest price to fair value of the 14 companies on the list.
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,030.30 | 45.40 | -0.50% |
| CAC 40 | 8,211.50 | 16.29 | 0.20% |
| DAX 40 | 24,868.69 | 329.35 | 1.34% |
| Dow JONES (US) | 48,977.18 | 594.79 | 1.23% |
| FTSE 100 | 10,004.57 | 53.43 | 0.54% |
| HKSE | 26,513.76 | 166.52 | 0.63% |
| NASDAQ | 23,395.82 | 160.19 | 0.69% |
| Nikkei 225 | 52,236.17 | 403.37 | 0.78% |
| NZX 50 Index | 13,648.86 | 61.63 | 0.45% |
| S&P 500 | 6,902.05 | 43.58 | 0.64% |
| S&P/ASX 200 | 8,718.30 | 53.00 | -0.60% |
| SSE Composite Index | 4,032.31 | 8.89 | 0.22% |